David H. Ilson, MD, PhD

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.

Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.

An investigational blood-based assay demonstrated efficacy in detecting multiple types of cancer, including gastrointestinal cancers, at various stages, according to study results presented at Gastrointestinal Cancers Symposium.

Anti-EGFR therapy showed promising efficacy for certain patients with non-V600 BRAF-mutated metastatic colorectal cancer, according to results of a multicenter, pooled analysis published in Clinical Cancer Research.

BARCELONA, Spain — Triplet therapy with encorafenib, cetuximab and binimetinib significantly extended OS compared with standard treatment for patients with BRAF V600E mutation-positive metastatic colorectal cancer, according to results of the phase 3 BEACON CRC trial presented at European Society for Medical Oncology Congress.

Vitamin D3 supplementation moderately prolonged PFS and, to a limited extent, RFS among patients with certain gastrointestinal cancers, according to results of two separate studies published in JAMA.